Qualification of classical biomarkers for Alzheimer’s Disease in a multiplex format in blood using a new technology

Protein biomarker profiling in biological fluids will soon become an established procedure in clinical diagnosis of neurodegenerative disease subtypes. Observed differences between technology platforms in performances can be attributed to technology principles and their development status, selection and characterization of antibody combinations, reproducibility of test results, and pre‐analytical factors and processing of samples. Combination of advantages of emerging technologies, together with availability of precision‐qualified assay formats and innovative sample processing procedures, will create additional possibilities for individual patient management using clinically validated protein biomarker panels.